Imbruvica beats chlorambucil in Phase III CLL/SLL trial

The Pharmacyclics LLC subsidiary of AbbVie Inc. (NYSE:ABBV) said Imbruvica ibrutinib met primary and secondary endpoints in its final analysis of the Phase III RESONATE-2 trial. The study compared Imbruvica with chlorambucil to treat chronic lymphocytic leukemia or small lymphocytic lymphoma in treatment-naive patients aged 65 and older.

Pharmacyclics said Imbruvica met the primary endpoint of improving progression-free survival (PFS) and secondary endpoints of improving overall survival (OS) and objective response rate (ORR). The company did not release specific data, which it plans to submit for presentation at an upcoming conference and publication in a peer-reviewed journal. AbbVie did not respond to inquiries. ...